MYRX - Myriad Pharmaceuticals, Inc.

Myrexis, Inc. (Myrexis) is a biotechnology company focused on discovering, developing and commercializing treatments for cancer. The Companys development pipeline includes clinical and pre-clinical product candidates. Myrexis retains all rights to all of its drug candidates and programs across all geographic markets and therapeutic indications. As of June30, 2010, the Company had two clinical-stage programs in oncology: Azixa and MPC-3100. In June 2010, Myrexis announced the suspension of its human immunodeficiency virus (HIV) maturation inhibitor programs. Azixa is the Companys advanced cancer drug candidate and is being developed for the treatment of advanced primary and metastatic tumors with brain involvement. MPC-3100 is an Hsp90 inhibitor Myrexis is developing for the treatment of cancer. The Companys research is primarily focused on oncology.